Do analysts prefer EVGN or CARM?

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 22,122.22%. Given Carisma Therapeutics' higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer TSE or EVGN?

Trinseo presently has a consensus target price of $1.00, indicating a potential upside of 334.78%. Given Trinseo's higher possible upside, research analysts plainly believe Trinseo is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinseo 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has stronger valuation & earnings, TSE or EVGN?

Evogene has lower revenue, but higher earnings than Trinseo. Evogene is trading at a lower price-to-earnings ratio than Trinseo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trinseo $3.13B 0.00 -$348.50M -$11.55 N/A Evogene $3.85M 1.23 -$8.48M -$1.39 N/A

Is TSE or EVGN more profitable?

Trinseo has a net margin of -13.15% compared to Evogene's net margin of -638.12%. Trinseo's return on equity of 0.00% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets Trinseo -13.15% N/A -11.72% Evogene -638.12% -158.82% -80.37%

Do analysts recommend SNES or EVGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senestech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is SNES or EVGN more profitable?

Senestech has a net margin of -304.22% compared to Evogene's net margin of -638.12%. Senestech's return on equity of -67.60% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets Senestech -304.22% -67.60% -49.21% Evogene -638.12% -158.82% -80.37%

Do analysts prefer GURE or EVGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gulf Resources 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts recommend EVGN or ORGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Origin Materials 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EVGN or ORGN more profitable?

Evogene has a net margin of -638.12% compared to Origin Materials' net margin of -1,742.04%. Origin Materials' return on equity of -120.66% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets Evogene -638.12% -158.82% -80.37% Origin Materials -1,742.04% -120.66% -99.50%

Evogene (EVGN) Competitors

$0.54 0.00 (-0.04%)

Closing price 07/24/2026 03:59 PM Eastern

Extended Trading

$0.54 -0.01 (-1.20%)

As of 07/24/2026 04:10 PM Eastern

Compare

EVGN vs. CARM, TSE, SNES, GURE, and ORGN

Should you buy Evogene stock or one of its competitors? MarketBeat compares Evogene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evogene include Carisma Therapeutics (CARM), Trinseo (TSE), Senestech (SNES), Gulf Resources (GURE), and Origin Materials (ORGN).

How does Evogene compare to Carisma Therapeutics?

Evogene (NASDAQ:EVGN) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Carisma Therapeutics has a net margin of -254.28% compared to Evogene's net margin of -638.12%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-638.12%	-158.82%	-80.37%
Carisma Therapeutics	-254.28%	N/A	-192.17%

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 22,122.22%. Given Carisma Therapeutics' higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Evogene has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.34, suggesting that its stock price is 1,034% less volatile than the broader market.

Evogene has higher earnings, but lower revenue than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	1.23	-$8.48M	-$1.39	N/A
Carisma Therapeutics	$10.77M	0.02	-$60.48M	$0.73	0.01

In the previous week, Evogene had 2 more articles in the media than Carisma Therapeutics. MarketBeat recorded 2 mentions for Evogene and 0 mentions for Carisma Therapeutics. Evogene's average media sentiment score of 0.83 beat Carisma Therapeutics' score of 0.00 indicating that Evogene is being referred to more favorably in the media.

Company	Overall Sentiment
Evogene	Positive
Carisma Therapeutics	Neutral

10.4% of Evogene shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 7.4% of Evogene shares are owned by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Evogene beats Carisma Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Evogene compare to Trinseo?

Trinseo (NYSE:TSE) and Evogene (NASDAQ:EVGN) are both small-cap chemicals companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

In the previous week, Evogene had 2 more articles in the media than Trinseo. MarketBeat recorded 2 mentions for Evogene and 0 mentions for Trinseo. Evogene's average media sentiment score of 0.83 beat Trinseo's score of 0.00 indicating that Evogene is being referred to more favorably in the news media.

Company	Overall Sentiment
Trinseo	Neutral
Evogene	Positive

Evogene has lower revenue, but higher earnings than Trinseo. Evogene is trading at a lower price-to-earnings ratio than Trinseo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinseo	$3.13B	0.00	-$348.50M	-$11.55	N/A
Evogene	$3.85M	1.23	-$8.48M	-$1.39	N/A

Trinseo has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Evogene has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Trinseo has a net margin of -13.15% compared to Evogene's net margin of -638.12%. Trinseo's return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinseo	-13.15%	N/A	-11.72%
Evogene	-638.12%	-158.82%	-80.37%

Trinseo presently has a consensus target price of $1.00, indicating a potential upside of 334.78%. Given Trinseo's higher possible upside, research analysts plainly believe Trinseo is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinseo	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

82.7% of Trinseo shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 4.5% of Trinseo shares are owned by insiders. Comparatively, 7.4% of Evogene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Trinseo and Evogene tied by winning 8 of the 16 factors compared between the two stocks.

How does Evogene compare to Senestech?

Senestech (NASDAQ:SNES) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Senestech has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Evogene has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

In the previous week, Senestech and Senestech both had 2 articles in the media. Senestech's average media sentiment score of 1.44 beat Evogene's score of 0.83 indicating that Senestech is being referred to more favorably in the media.

Company	Overall Sentiment
Senestech	Positive
Evogene	Positive

5.2% of Senestech shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 2.2% of Senestech shares are held by company insiders. Comparatively, 7.4% of Evogene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Senestech has a net margin of -304.22% compared to Evogene's net margin of -638.12%. Senestech's return on equity of -67.60% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senestech	-304.22%	-67.60%	-49.21%
Evogene	-638.12%	-158.82%	-80.37%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senestech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Senestech has higher earnings, but lower revenue than Evogene. Senestech is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senestech	$2.22M	3.32	-$6.38M	-$1.89	N/A
Evogene	$3.85M	1.23	-$8.48M	-$1.39	N/A

Summary

Evogene beats Senestech on 7 of the 13 factors compared between the two stocks.

How does Evogene compare to Gulf Resources?

Gulf Resources (NASDAQ:GURE) and Evogene (NASDAQ:EVGN) are both small-cap chemicals companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gulf Resources	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Evogene had 1 more articles in the media than Gulf Resources. MarketBeat recorded 2 mentions for Evogene and 1 mentions for Gulf Resources. Gulf Resources' average media sentiment score of 1.89 beat Evogene's score of 0.83 indicating that Gulf Resources is being referred to more favorably in the media.

Company	Overall Sentiment
Gulf Resources	Very Positive
Evogene	Positive

3.3% of Gulf Resources shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 3.2% of Gulf Resources shares are held by company insiders. Comparatively, 7.4% of Evogene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Gulf Resources has a beta of -0.13, suggesting that its stock price is 113% less volatile than the broader market. Comparatively, Evogene has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Evogene has lower revenue, but higher earnings than Gulf Resources. Evogene is trading at a lower price-to-earnings ratio than Gulf Resources, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gulf Resources	$7.66M	0.69	-$58.94M	-$48.05	N/A
Evogene	$3.85M	1.23	-$8.48M	-$1.39	N/A

Gulf Resources has a net margin of 0.00% compared to Evogene's net margin of -638.12%. Gulf Resources' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gulf Resources	N/A	N/A	N/A
Evogene	-638.12%	-158.82%	-80.37%

Summary

Evogene beats Gulf Resources on 9 of the 15 factors compared between the two stocks.

How does Evogene compare to Origin Materials?

Evogene (NASDAQ:EVGN) and Origin Materials (NASDAQ:ORGN) are both small-cap chemicals companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

10.4% of Evogene shares are owned by institutional investors. Comparatively, 29.9% of Origin Materials shares are owned by institutional investors. 7.4% of Evogene shares are owned by company insiders. Comparatively, 2.8% of Origin Materials shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Evogene has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Origin Materials has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

In the previous week, Evogene had 2 more articles in the media than Origin Materials. MarketBeat recorded 2 mentions for Evogene and 0 mentions for Origin Materials. Evogene's average media sentiment score of 0.83 beat Origin Materials' score of 0.00 indicating that Evogene is being referred to more favorably in the media.

Company	Overall Sentiment
Evogene	Positive
Origin Materials	Neutral

Evogene has higher earnings, but lower revenue than Origin Materials. Evogene is trading at a lower price-to-earnings ratio than Origin Materials, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	1.23	-$8.48M	-$1.39	N/A
Origin Materials	$13.97M	0.37	-$249.70M	-$47.83	N/A

Evogene has a net margin of -638.12% compared to Origin Materials' net margin of -1,742.04%. Origin Materials' return on equity of -120.66% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-638.12%	-158.82%	-80.37%
Origin Materials	-1,742.04%	-120.66%	-99.50%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Origin Materials	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Evogene beats Origin Materials on 11 of the 15 factors compared between the two stocks.

Get Evogene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVGN vs. The Competition

Export

Metric	Evogene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.73M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.39	21.29	27.11	23.64
Price / Sales	1.23	161.81	496.78	76.82
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	0.40	7.88	10.28	6.07
Net Income	-$8.48M	$23.86M	$3.60B	$331.99M
7 Day Performance	-13.75%	-3.82%	-1.27%	-0.63%
1 Month Performance	36.27%	-2.61%	-0.37%	-2.00%
1 Year Performance	-58.59%	32.79%	18.30%	13.62%

Evogene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVGN Evogene	0.8714 of 5 stars	$0.54 0.0%	N/A	-59.8%	$4.73M	$3.85M	N/A	140	Gap Up
CARM Carisma Therapeutics	1.9118 of 5 stars	$0.01 -8.8%	$1.00 +19,130.8%	-98.9%	$218K	$10.77M	0.01	20	Gap Down
TSE Trinseo	1.2431 of 5 stars	$0.23 flat	$1.00 +334.8%	N/A	$8.10M	$3.13B	N/A	2,950
SNES Senestech	2.763 of 5 stars	$1.37 -4.2%	N/A	-75.3%	$7.58M	$2.22M	N/A	30	Short Interest Decrease Gap Up
GURE Gulf Resources	0.6229 of 5 stars	$3.49 -7.9%	N/A	-49.0%	$5.84M	$7.66M	N/A	420	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVGN) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evogene (EVGN) Competitors

EVGN vs. CARM, TSE, SNES, GURE, and ORGN

How does Evogene compare to Carisma Therapeutics?

Summary

How does Evogene compare to Trinseo?

Summary

How does Evogene compare to Senestech?

Summary

How does Evogene compare to Gulf Resources?

Summary

How does Evogene compare to Origin Materials?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN vs. The Competition

Evogene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evogene (EVGN) Competitors

EVGN vs. CARM, TSE, SNES, GURE, and ORGN

How does Evogene compare to Carisma Therapeutics?

Is EVGN or CARM more profitable?

Do analysts prefer EVGN or CARM?

Which has more volatility and risk, EVGN or CARM?

Which has better valuation and earnings, EVGN or CARM?

Does the media prefer EVGN or CARM?

Do institutionals & insiders hold more shares of EVGN or CARM?

Summary

How does Evogene compare to Trinseo?

Does the media refer more to TSE or EVGN?

Which has stronger valuation & earnings, TSE or EVGN?

Which has more risk & volatility, TSE or EVGN?

Is TSE or EVGN more profitable?

Do analysts prefer TSE or EVGN?

Do insiders & institutionals believe in TSE or EVGN?

Summary

How does Evogene compare to Senestech?

Which has more risk & volatility, SNES or EVGN?

Does the media refer more to SNES or EVGN?

Do insiders and institutionals believe in SNES or EVGN?

Is SNES or EVGN more profitable?

Do analysts recommend SNES or EVGN?

Which has stronger earnings & valuation, SNES or EVGN?

Summary

How does Evogene compare to Gulf Resources?

Do analysts prefer GURE or EVGN?

Does the media favor GURE or EVGN?

Do institutionals & insiders have more ownership in GURE or EVGN?

Which has more volatility and risk, GURE or EVGN?

Which has stronger earnings & valuation, GURE or EVGN?

Is GURE or EVGN more profitable?

Summary

How does Evogene compare to Origin Materials?

Do insiders & institutionals hold more shares of EVGN or ORGN?

Which has more volatility & risk, EVGN or ORGN?

Does the media prefer EVGN or ORGN?

Which has stronger earnings & valuation, EVGN or ORGN?

Is EVGN or ORGN more profitable?

Do analysts recommend EVGN or ORGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN vs. The Competition

Evogene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools